Literature DB >> 27311763

Pentoxifylline Alleviates Early Brain Injury in a Rat Model of Subarachnoid Hemorrhage.

Ethem Goksu1, Ozgur Dogan2, Pınar Ulker3, Gamze Tanrıover4, Esma Konuk4, Sayra Dilmac4, Ebru Kirac5, Necdet Demır4, Mutay Aslan6.   

Abstract

BACKGROUND: Subarachnoid hemorrhage (SAH) is a severe cerebrovascular disease frequently caused by ruptured aneurysms. Early brain injury (EBI) is the primary cause of morbidity and mortality in patients diagnosed with SAH and is associated with increased intracranial pressure, decreased cerebral blood flow and cerebral ischemia. Pentoxifylline (PTX) is a methylxanthine derivative clinically proven to improve perfusion in the peripheral microcirculation and has been shown to have neuroprotective effects in brain trauma and global cerebral ischemia in experimental animal models. This study aimed to determine the effect of PTX in experimental SAH, which has not been investigated yet.
METHODS: An experimental SAH model was induced in male Wistar rats by autologous blood injection into the prechiasmatic cistern, and PTX was injected intraperitoneally immediately after SAH. The effects of PTX were evaluated 24 h after SAH via assessing the cerebral ultrastructure via transmission electron microscopy (TEM). Brain edema, blood-brain barrier (BBB) permeability, red blood cell deformability, tumor necrosis factor-alpha (TNF-alpha), nitrite-nitrate levels and apoptotic neuron death were also determined 24 h after SAH. The BBB permeability was measured by Evans blue (EB) extravasation, erythrocyte deformability was determined by filtration technique, and TNF-alpha and reactive nitrogen metobolites were analyzed in brain tissue by ELISA and spectral analysis, respectively. Apoptotic neurons were determined in brain sections by cleaved caspase-3 immunohistochemical analysis, and expression intensity was quantified using image J software.
RESULTS: Cerebral ultrastructure in SAH group animals revealed intense perivascular edema and distortion in the astrocyte foot processes. PTX treatment attenuated structural deterioration due to SAH. Brain water content, BBB permeability, TNF-alpha, nitrite-nitrate levels and apoptotic neuronal death were significantly increased 24 h after SAH and were significantly alleviated by PTX treatment. There was no significant change in red cell deformability after SAH.
CONCLUSIONS: Our results show that PTX reduces brain edema, BBB permeability, TNF-alpha expression, reactive nitrogen metobolites and apopotosis in experimental SAH. Based on our findings we suggest that PTX exerts neuroprotection against SAH-induced EBI, which might be associated with the inhibition of inflammation and apoptotic neuronal cell death.

Entities:  

Keywords:  Apoptosis; Early brain injury; Inflammation; Pentoxifylline; Subarachnoid hemorrhage

Mesh:

Substances:

Year:  2016        PMID: 27311763     DOI: 10.1007/s00701-016-2866-5

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  4 in total

1.  Evaluation of the protective effect of pentoxifylline on carrageenan-induced chronic non-bacterial prostatitis in rats.

Authors:  Mahboobeh Hajighorbani; Mahmood Ahmadi-Hamedani; Elaheh Shahab; Farzad Hayati; Khatereh Kafshdoozan; Keivan Keramati; Amin Hossein Amini
Journal:  Inflammopharmacology       Date:  2017-03-09       Impact factor: 4.473

Review 2.  The blood-brain barrier and the neurovascular unit in subarachnoid hemorrhage: molecular events and potential treatments.

Authors:  Peter Solár; Alemeh Zamani; Klaudia Lakatosová; Marek Joukal
Journal:  Fluids Barriers CNS       Date:  2022-04-11

Review 3.  The role of the astrocyte in subarachnoid hemorrhage and its therapeutic implications.

Authors:  Rong Li; Min Zhao; Di Yao; Xiangyue Zhou; Cameron Lenahan; Ling Wang; Yibo Ou; Yue He
Journal:  Front Immunol       Date:  2022-09-29       Impact factor: 8.786

4.  Expression of caspase-3, Bax and Bcl-2 in hippocampus of rats with diabetes and subarachnoid hemorrhage.

Authors:  Xin He; Jiankui Sun; Xiaoyu Huang
Journal:  Exp Ther Med       Date:  2017-11-03       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.